| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Property and equipment, net | 2,899 | |||
| Intangible assets, net | 3,122 | |||
| Prepaid expenses and other current assets | 6,738 | |||
| Short-term restricted cash for other investments | 0 | |||
| Cash and cash equivalents | 61,940 | |||
| Securities carried at fair value | 34,003 | |||
| Total current assets | 102,681 | |||
| Other investments held at fair value | 16,816 | |||
| Other investments | 53,947 | |||
| Other assets | 389 | |||
| Operating lease right-of-use asset, net | 2,803 | |||
| Goodwill | 331 | |||
| Digital assets | 6,216 | |||
| Total assets | 189,204 | |||
| Accrued liabilities | 14,514 | |||
| Current portion of long-term debt | 0 | |||
| Other current liabilities | 397 | |||
| Current portion of lease liabilities | 437 | |||
| Accounts payable | 4,039 | |||
| Short-term convertible promissory notes and derivative liability - related party | 2,466 | |||
| Short-term convertible promissory notes and derivative liability | 3,694 | |||
| Total current liabilities | 25,547 | |||
| Other liabilities | 3,033 | |||
| Non-current portion of lease liability | 2,619 | |||
| Long-term debt, net | 0 | |||
| Contingent consideration liability - related party | 110 | |||
| Pre-funded warrant liabilities | 13,758 | |||
| Contingent consideration liability | 212 | |||
| Total liabilities | 45,279 | |||
| Accumulated deficit | -754,367 | |||
| Common stock, 0.10 par value (0.12 and 0.10 par value at june 30, 2025 and december 31, 2024, respectively) 750,000,000 shares authorized at june 30, 2025 and december 31, 2024, respectively 212,244,597 and 167,959,752 shares issued and outstanding at june 30, 2025 and december 31, 2024, respectively | 23,547 | |||
| Additional paid-in capital | 895,486 | |||
| Accumulated other comprehensive loss | -20,928 | |||
| Total stockholders' equity attributable to atai life sciences n.v. stockholders | 143,738 | |||
| Noncontrolling interests | 187 | |||
| Total stockholders equity | 143,925 | |||
| Total liabilities and stockholders' equity | 189,204 | |||
ATAI Life Sciences N.V. (ATAI)
ATAI Life Sciences N.V. (ATAI)